Triple therapy shows promise for aggressive prostate cancer

This early-phase study tested a combination of enzalutamide (a hormone-blocking drug), radiation therapy, and standard hormone therapy in 25 men with intermediate or high-risk prostate cancer. The main goal was to check for side effects and find the best way to give the treatment. Researchers also tracked PSA levels and quality of life. The approach aims to control the disease, not cure it, as ongoing hormone therapy is typically needed.